The number of patients with cancer is growing, and patients continue to struggle with treatment side effects, leading to dose reduction or discontinuation of cancer therapeutics. This creates an opportunity for a new generation of cancer supportive agents to help an underserved population of patients in need. To find out more in this regard, BioSpectrum Asia spoke to Mike McCullar, Chief Executive Officer, OnQuality Pharmaceuticals in detail. The company has operations in the US and China. Edited excerpts;
What is the market landscape for cancer supportive care therapeutics in Asia?
Cancer is the second most prevalent cause of death worldwide, prompting many to develop therapeutics to help patients in need. Approved cancer therapies provide patients with the hope of complete remission but are also characterised by potentially severe side effects. This holds true for classical therapies, such as chemotherapy, surgery, and radiation, as well as modern approaches such as targeted immunotherapies.
Due to the growing burden of cancer in Asia, accounting for over 30 per cent of all cases worldwide, and an increasing number of cancer survivors, cancer-related morbidities have been rapidly growing. There is a significant unmet need in cancer supportive care with limited treatment options. In fact, skin toxicities are among the most common adverse events associated with cancer treatments and gastrointestinal (GI) side effects are correlated with high rates of cancer therapy discontinuation. We are developing therapies to treat both of these side effects.
This story is from the June 2022 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the June 2022 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Ushering Fourth Industrial Revolution in Telangana
Taking advantage of the 21st edition of BioAsia 2024 at the Hyderabad International Convention Centre (HICC) in Madhapur, the Government of Telangana, a southern state in India, leveraged the confluence of the global platform to spearhead initiatives aimed at propelling the state into the forefront of the Fourth Industrial Revolution (C4IR).
How Indian Biotech Investments are on a Doubling Spree
A latest report by Ankur Capital provides a closer look at the investments made in biotechnology in the last decade in the country.
"AI will be integrally involved in not only the diagnosis of cancer but also in determining the prognosis and best therapeutic option”
South Korea-based Deep Bio, a pioneering artificial intelligence (AI) healthcare firm focused on cancer pathology, is making waves in the industry.
"Because of its specificity and selectivity, ADCS have the potential to reduce adverse side effects and improve patient survival"
Japan-headquartered Daiichi Sankyo, the global healthcare company, launched its subsidiary Daiichi Sankyo Singapore Pte. Ltd. to bridge unmet needs in oncology.
Can Test, Treat, Track Beat Malaria?
Malaria has long been a major public health concern in the Asia Pacific region, particularly in South East Asia (SEA) affecting millions of people.
Engineering CAR T cell sharpshooters
Approved CAR T-cell therapies have shown remarkable results in patients with certain types of blood cancers.
Addressing Challenges in Cell Therapy Manufacturing
Even with significant advancements, there are still anumber of issues with cell therapy manufacturing that need to be resolved as production grows.
"We anticipate India will adopt decentralised models for managing CGTs, ensuring closer proximity between patients and treatment facilities"
Cell and gene therapy (CGT) expert from Germany, Miltenyi Biotec has recently announced its entry into the Indian market to provide researchers, scientists and clinicians easier access to expertise, research, and manufacturing solutions.
Addressing Accessibility and Affordability of CELL & GENE THERAPIES
Cell and gene therapies (CGT) are one of the hottest sectors in the pharmaceutical industry.
Korea designs sweat resistant wearable robot sensor
New electromyography (EMG) sensor technology that allows the long-term stable control of wearable robots and is not affected by the wearer's sweat and dead skin has gained attention recently.
